RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.Expert Opin Investig Drugs. 2017 Jan;26(1):109-119....

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.PMID: 28149332 Free PMC article.

RRx-001 protects against cisplatin-induced toxicities.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P.J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17.PMID: 28417195

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.PMID: 28448172 Free PMC article.

Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Huang Z, Fu J, Zhang Y.J Med Chem. 2017 Sep 28;60(18):7617-7635. doi: 10.1021/acs.jmedchem.6b01672. Epub 2017 May 23.PMID: 28505442 Review.